22 completed. 22 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 22 |
| Phase 1 | 3 | Completed 3 |
Follow Recurrent Osteosarcoma: new trials by email Literature Review of Recurrent Osteosarcoma trials Research Report on Recurrent Osteosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors Laboratory Biomarker Analysis, Pepinemab, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 26 | 2018-01-31 | 2024-07-15 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Biospecimen Collection, Computed Tomography, FDG-Positron Emission Tomography - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2017-11-28 | 2026-04-21 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Olaparib - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 6 | 2017-09-14 | 2024-12-11 |
| Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma Glembatumumab Vedotin, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Osteosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2016-02-16 | 2022-01-18 |
| Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma Dinutuximab, Laboratory Biomarker Analysis, Pharmacological Study - Metastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2016-02-04 | 2023-10-26 |
| Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma Denosumab, Laboratory Biomarker Analysis, Pharmacological Study - Metastatic Osteosarcoma, Recurrent Osteosarcoma | Phase 2 | Completed | Children's Oncology Group | 56 | 2015-11-21 | 2024-01-22 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
| Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas Pazopanib Hydrochloride, Oral Topotecan Hydrochloride, Laboratory Biomarker Analysis - Adult Liposarcoma, Metastatic Liposarcoma | Phase 2 | Completed | Northwestern University | 178 | 2015-03-21 | 2022-06-07 |
| Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma Eribulin Mesylate, Pharmacological Study - Recurrent Osteosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2014-08-01 | 2020-05-19 |
| Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus - Childhood Alveolar Soft Part Sarcoma, Childhood Angiosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 46 | 2012-06-18 | 2018-12-11 |
| Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Alisertib, Laboratory Biomarker Analysis, Pharmacological Study - Hepatoblastoma, Previously Treated Childhood Rhabdomyosarcoma | Phase 2 | Completed | Children's Oncology Group | 118 | 2011-02-01 | 2020-05-13 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study - Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 78 | 2010-06-01 | 2018-08-15 |
| Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma Cixutumumab, Laboratory Biomarker Analysis, Temsirolimus - Metastatic Osteosarcoma, Recurrent Adult Soft Tissue Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 178 | 2009-11-01 | 2015-07-30 |
| Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery therapeutic angiotensin-(1-7), laboratory biomarker analysis - Bone Cancer, Chondrosarcoma | Phase 2 | Completed | Wake Forest University Health Sciences | 20 | 2009-10-01 | 2018-07-05 |
| Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors cixutumumab, laboratory biomarker analysis - Adult Rhabdomyosarcoma, Adult Synovial Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 116 | 2009-01-01 | 2015-03-30 |
| Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) sorafenib tosylate, therapeutic conventional surgery, laboratory biomarker analysis - Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Osteosarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 15 | 2006-06-01 | 2014-04-30 |
| Ixabepilone in Treating Young Patients With Refractory Solid Tumors ixabepilone - Adult Rhabdomyosarcoma, Adult Synovial Sarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 120 | 2006-04-01 | 2014-11-14 |
| Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment oxaliplatin - Childhood Central Nervous System Germ Cell Tumor, Childhood Extragonadal Germ Cell Tumor | Phase 2 | Completed | National Cancer Institute (NCI) | 180 | 2004-10-01 | 2013-06-05 |
Showing 20 of 22. Sign in to see all of them.
Osteosarcoma (22) · Neuroectodermal Tumors, Primitive, Peripheral (13) · Sarcoma (12) · Neuroblastoma (11) · Rhabdomyosarcoma (9) · Hepatoblastoma (7) · Wilms Tumor (6) · Lymphoma, Non-Hodgkin (5) · Medulloblastoma (5) · Ependymoma (4) · Familial ependymoma (4) · Glioma (4) · Histiocytosis, Langerhans-Cell (4) · Rhabdoid Tumor (4) · Sarcoma, Ewing (4)
Neoplasms (22) · Neoplasms by Histologic Type (22) · Neoplasms, Bone Tissue (22) · Neoplasms, Connective Tissue (22) · Neoplasms, Connective and Soft Tissue (22) · Neoplasms, Germ Cell and Embryonal (14) · Neoplasms, Glandular and Epithelial (14) · Neoplasms, Nerve Tissue (14) · Neoplasms, Neuroepithelial (14) · Neuroectodermal Tumors, Primitive (14) · Neuroectodermal Tumors (13) · Neoplasms by Site (10) · Sarcoma (10) · Myosarcoma (9) · Neoplasms, Muscle Tissue (9)
cixutumumab (3) · Sirolimus (2) · temsirolimus (2) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (1) · CR011-vcMMAE (1) · CTLA-4 Antigen (1) · Colony-Stimulating Factors (1) · Denosumab (1) · HhAntag691 (1) · Imatinib Mesylate (1) · Ipilimumab (1) · Irinotecan (1) · LY3023414 (1) · MLN 8237 (1) · Magnetic Resonance Spectroscopy (1)
National Cancer Institute (NCI) (16) · Children's Oncology Group (4) · Northwestern University (1) · Wake Forest University Health Sciences (1)
United States (22) · Canada (9) · Puerto Rico (7) · Australia (2) · New Zealand (1)
Brenda Weigel, MD (1) · Brigitte Widemann (1) · Crystal L Mackall (1) · Emily G Greengard (1) · Jeffrey Morgan (1) · Julia Glade-Bender (1) · Katherine A Janeway (1) · Lars Wagner (1) · Lisa Bomgaars (1) · Lisa M Kopp (1) · Mark Agulnik (1) · Mason Bond (1) · Michael Isakoff (1) · Mrinal Gounder (1) · Orren Beaty (1)
PMID 31401903, PMID 22347360, PMID 23477833, PMID 30777875, PMID 31586757, PMID 32192573, PMID 34435684, PMID 38520670, PMID 38815151, PMID 39298716
U10CA098543 (8), U10CA180886 (8), P30CA008748 (2), UM1CA097452 (2), N01CM00032 (1), N01CM00038 (1), N01CM00071 (1), N01CM00100 (1), N01CM62206 (1), P30CA060553 (1), U01CA062490 (1), U01CA069856 (1)